Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Family History and Solar Insolation in Bipolar I Disorder.

Acta psychiatrica Scandinavica·2026
Same author

Effect of beta-glucan on oxidative stress, inflammation, hormonal and histopathological changes in dehydroepiandrosterone-induced polycystic ovary syndrome.

Biotechnic & histochemistry : official publication of the Biological Stain Commission·2025
Same author

Evaluatıng the Role of Overactıve Bladder Dıagnosıs ın Predıctıng the Rısk of Postspınal Hypotensıon Durıng Electıve Cesarean Sectıon Operatıons: Randomızed Trıple-Blınded Study.

Nigerian journal of clinical practice·2025
Same author

Do Gene Polymorphisms Play a Role in Newborn Hyperbilirubinemia?

Balkan journal of medical genetics : BJMG·2024
Same author

An effective approach for the treatment of severe punctal stenosis: Bicanalicular silicone tube intubation with pigtail probe.

Journal francais d'ophtalmologie·2024
Same author

The relationship of promoter methylation of calcium voltage-gated channel alpha 1 and interleukin-16 to primary osteoarthritis.

European review for medical and pharmacological sciences·2023

Related Experiment Video

Updated: Jul 13, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

ACE gene polymorphism in peripheral vascular disease.

Y Başar1, N Salmayenli, M Aksoy

  • 1Department of General Surgery, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey.

Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme
|July 6, 2007
PubMed
Summary

The angiotensin converting enzyme (ACE) ID genotype may increase the risk of peripheral vascular disease in Turkish patients. ACE activity was higher in patients, and ACE genotype frequencies differed between patients and controls.

More Related Videos

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

Related Experiment Videos

Last Updated: Jul 13, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

Area of Science:

  • Cardiovascular Science
  • Genetics
  • Medical Research

Background:

  • Peripheral vascular disease (PVD) is a manifestation of atherosclerosis.
  • The angiotensin converting enzyme (ACE) insertion/deletion (I/D) polymorphism has been linked to atherosclerosis.
  • Understanding genetic predispositions like ACE polymorphism is crucial for PVD research.

Purpose of the Study:

  • To investigate the association between ACE I/D polymorphism and PVD in a Turkish population.
  • To examine the relationship between serum ACE activity and ACE genotypes in PVD patients and healthy controls.
  • To identify potential genetic risk factors for PVD in Western Turkey.

Main Methods:

  • Genotyping for ACE I/D polymorphism in 78 PVD patients and 73 healthy controls.
  • Measurement of serum ACE activity in all participants.
  • Statistical analysis to compare genotype frequencies and ACE activity between groups.

Main Results:

  • Serum ACE activity was significantly higher in PVD patients compared to controls (p<0.05).
  • ACE genotype frequencies differed between patients (DD: 28.2%, II: 18%, ID: 53.8%) and controls (DD: 42.5%, II: 20.5%, ID: 37%).
  • Individuals with the II genotype had significantly lower serum ACE activity than those with ID and DD genotypes (p<0.05).

Conclusions:

  • The ACE ID genotype may represent a risk factor for peripheral vascular disease.
  • Serum ACE activity is elevated in Turkish PVD patients.
  • Further research is warranted to clarify the role of ACE polymorphism in PVD pathogenesis.